Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Gross Margin % : 63.07% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Panacea Life Sciences Holdings's Gross Profit for the three months ended in Mar. 2024 was $0.67 Mil. Panacea Life Sciences Holdings's Revenue for the three months ended in Mar. 2024 was $1.06 Mil. Therefore, Panacea Life Sciences Holdings's Gross Margin % for the quarter that ended in Mar. 2024 was 63.07%.

The historical rank and industry rank for Panacea Life Sciences Holdings's Gross Margin % or its related term are showing as below:

PLSH' s Gross Margin % Range Over the Past 10 Years
Min: 22.14 Med: 25.3 Max: 56.57
Current: 56.57

During the past 4 years, the highest Gross Margin % of Panacea Life Sciences Holdings was 56.57%. The lowest was 22.14%. And the median was 25.30%.

PLSH's Gross Margin % is ranked better than
67.07% of 987 companies
in the Drug Manufacturers industry
Industry Median: 46.24 vs PLSH: 56.57

Panacea Life Sciences Holdings had a gross margin of 63.07% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Panacea Life Sciences Holdings was 0.00% per year.

Panacea Life Sciences Holdings Gross Margin % Historical Data

The historical data trend for Panacea Life Sciences Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings Gross Margin % Chart

Panacea Life Sciences Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross Margin %

22.14

26.26

24.34

47.04

Panacea Life Sciences Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross Margin %	Get a 7-Day Free Trial											33.38	50.88	42.24	56.98	63.07

Competitive Comparison of Panacea Life Sciences Holdings's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Life Sciences Holdings's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's Gross Margin % falls into.

Panacea Life Sciences Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Panacea Life Sciences Holdings's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1.1	/	2.385
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(2.385 - 1.263)	/	2.385
	=	47.04 %

Panacea Life Sciences Holdings's Gross Margin for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0.7	/	1.056
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(1.056 - 0.39)	/	1.056
	=	63.07 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Panacea Life Sciences Holdings (OTCPK:PLSH) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Panacea Life Sciences Holdings had a gross margin of 63.07% for the quarter that ended in Mar. 2024 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Panacea Life Sciences Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121

Website

https://www.panacealife.com

Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.

Executives

Leslie Buttorff	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER	16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger	director	5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman	officer: CONTROLLER & PRIN ACTNG OFCR	16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc.	10 percent owner	8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner	10 percent owner	65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert	director	170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du	officer: Chief Growth Officer	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis	director	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky	director, 10 percent owner	332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz	director	332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson	officer: Chief Strategy Officer	80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi	officer: President	510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert	director, officer: Executive Chairman	36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price	director	4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval	director	NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019